17 2. DETERMINATION OF THE IPI MEASURE › 2.1. Proportionality and adequacy of a possible IPI measure with regard to the identified measures and practices › 2.1.1. The identified measures and practices, Regulation (EU) 2025/1197

In forcesince 19 Jun 2025

First, the Commission found that, through such measures and practices, the GOC has put in place an overarching system of generally applicable preferences for the procurement of domestic medical devices which significantly impairs the access of Union operators and Union-made medical devices to the public procurement market of the PRC [‘The analysis of the measures and practices under investigation shows that through such measures and practices, the PRC has put in place a multilayered overarching system of generally applicable preferences for the procurement of domestic medical devices that has led to a systematic discrimination against imported medical devices and foreign economic operators, implementing a comprehensive “Buy China” policy’ (see Section V of the investigation report for further details).]. The central feature of this system is a legally binding obligation imposed on contracting entities to procure domestic medical devices whenever they are in competition with imported ones and constitute a reasonable alternative. The discriminatory nature of this general obligation is strengthened by burdensome approval procedures [When domestic goods are not available or cannot be acquired on reasonable commercial terms in the PRC, the procurement of imported goods is subject to a specific assessment and approval procedure laid down in the Administrative Measures for the procurement of imported goods. The approval, granted by the local financial departments, is based on the assessment by an expert group of whether there are goods produced in the PRC with technical specifications and functional use comparable to those of the imported goods (see Section 2.1.2 of the SWD, recitals 19 to 27 for further details).] for the procurement of imported medical devices, which significantly constrain the ability of contracting entities to procure imported medical devices. Furthermore, within this framework, preference is given to imported medical devices that are associated with the transfer of technology to domestic companies [‘Article 5 of the Administrative Measures lays down the principle that purchasing imported goods should be “conducive to indigenous innovation or digestion and absorption of core technologies by domestic enterprises” and requires to “give priority to purchasing goods that transfer technology” or “provide training services and other compensation trade measures”. Pursuant to Article 15, this priority must be specified in the procurement documents for the purchase of the imported goods’ (see recital 20 of the SWD).]. The system is further reinforced by sector specific measures [‘Document 551 lays down requirements on all local authorities to increase the procurement of domestic goods for 178 categories of medical devices. The target share of domestic medical devices varies between 25 % and 100 %, with a 100 % target for 137 categories of medical devices’ (see recital 28 of the SWD).], which are set in the form of instructions by the GOC to public hospitals to achieve specific domestic procurement targets for several categories of medical devices calling for the full exclusion of imported medical devices in 137 categories. Finally, high-performance medical devices are identified in the Made in China 2025 Strategy [‘The “Made in China 2025 technology roadmap for key areas” (the “MIC Roadmap”), which specifies goals for each industry identified in the MIC 2025, sets specific targets for the share of domestically produced high-end medical devices procured by county hospitals, which should reach 50 % by 2020, 70 % by 2025, and 95 % by 2030’ (see recital 6 of the SWD).], resulting in the instruction to county hospitals to reach very high targets for the share of procurement of domestically produced high-end medical devices, i.e. 70 % by 2025 and 95 % by 2030, which would de facto reduce to near zero the scope for access of imported products to a significant part of the Chinese public procurement market.